tiprankstipranks

Fosun Pharma Reveals Henlius Buyout Terms

Fosun Pharma Reveals Henlius Buyout Terms

Shanghai Fosun Pharmaceutical (Group) Co (HK:2196) has released an update.

Shanghai Fosun Pharmaceutical announces a revised proposal for the privatization of Henlius, allowing shareholders to choose between a cash payment or shares in newly established rollover entities. This move, aiming to withdraw Henlius from public listing, offers a cash alternative of HK$24.60 per share or an equivalent share exchange, reflecting the company’s strategic consolidation efforts.

For further insights into HK:2196 stock, check out TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App